

Appendix B, Table 9. Characteristics of the CD4 Post-Attachment Inhibitor

(Last updated June 3, 2021; last reviewed June 3, 2021) (Page 1 of 1)

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events
Ibalizumab (IBA) <i>Trogarzo</i>	Trogarzo: <ul style="list-style-type: none"> Single-dose 2-mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab 	Trogarzo: <ul style="list-style-type: none"> Administer a single loading dose of IBA 2,000-mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800-mg IV infusion over 15 minutes every 2 weeks. See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring patients who are receiving IBA. 	~64 hours	Not well defined	Diarrhea Dizziness Nausea Rash Hypersensitivity, including anaphylaxis and infusion-related reactions have been reported.

Key: IBA = ibalizumab; IV = intravenous